Table 4.
Univariate and multivariate logistic regression analysis.
| Variable | Levels | OR (univariable) | OR (multivariable) |
|---|---|---|---|
| Age(years) | 0.96 (0.92 - 0.99, p=.026) | 0.96 (0.91 - 1.01, p=.152) | |
| Gender, n (p%) | male | ||
| female | 1.22 (0.61 - 2.47, p=.572) | ||
| H(cm) | 0.99 (0.95 - 1.03, p=.570) | ||
| Wt(kg) | 0.99 (0.96 - 1.01, p=.270) | ||
| BMI(kg/m2) | 1.01 (0.98 - 1.04, p=.620) | ||
| Dialysis time(years) | 0.90 (0.80 - 1.00, p=.056) | ||
| Dialysis modality, n (p%) | Hemodialysis | ||
| Peritoneal dialysis | 1.23 (0.28 - 5.39, p=.782) | ||
| Cinacalcet, n (p%) | no | ||
| yes | 1.41 (0.59 - 3.37, p=.434) | ||
| Calcitriol, n (p%) | no | ||
| yes | 0.77 (0.38 - 1.58, p=.480) | ||
| Paricalcitol, n (p%) | no | ||
| yes | 0.17 (0.02 - 1.58, p=.119) | ||
| Alfacalcidol, n (p%) | no | ||
| yes | 0.27 (0.05 - 1.46, p=.129) | ||
| Lanthanum carbonate, n (p%) | no | ||
| yes | 2.29 (0.44 - 11.83, p=.321) | ||
| Bisphosphonates, n (p%) | no | ||
| yes | 0.00 (0.00-Inf, p=.987) | ||
| Hypertension, n (p%) | no | ||
| yes | 2.16 (0.94 - 4.94, p=.070) | ||
| Coro2ry heart disease, n (p%) | no | ||
| yes | 0.80 (0.35 - 1.86, p=.608) | ||
| Diabetes, n (p%) | no | ||
| yes | 0.71 (0.17 - 2.99, p=.645) | ||
| Cerebrovascular disease, n (p%) | no | ||
| yes | 12614529.59 (0.00-Inf, p=.986) | ||
| Osteoporosis, n (p%) | no | ||
| yes | 0.00 (0.00-Inf, p=.988) | ||
| Fracture, n (p%) | no | ||
| yes | 0.00 (0.00-Inf, p=.988) | ||
| Surgical time(minutes) | 1.00 (1.00 - 1.01, p=.523) | ||
| Number of resections | 3.18 (1.44 - 7.00, p=.004) | 1.55 (0.38 - 6.23, p=.540) | |
| TPTX, n (p%) | 2.76 (1.02 - 7.48, p=.045) | 2.60 (0.61 - 11.02, p=.194) | |
| SPTX, n (p%) | 0.31 (0.11 - 0.88, p=.029) | 1.46 (0.17 - 12.90, p=.732) | |
| TPTX+AT, n (p%) | 0.98 (0.47 - 2.06, p=.958) | ||
| Hb(g/L) | 0.99 (0.96 - 1.01, p=.176) | ||
| WBC (109/L) | 0.90 (0.73 - 1.12, p=.352) | ||
| CRP(mg/L) | 1.04 (0.97 - 1.12, p=.280) | ||
| Ca (mmol/L) | 0.10 (0.02 - 0.63, p=.014) | 0.06 (0.00 - 1.15, p=.062) | |
| K(mmol/L) | 1.43 (0.86 - 2.40, p=.171) | ||
| P(mmol/L) | 1.00 (0.53 - 1.90, p=.990) | ||
| Pre-PTH(pg/ml) | 1.00 (1.00 - 1.00, p<.001) | 1.00 (1.00 - 1.00, p=.003) | |
| PTH at skin closure(pg/ml) | 1.00 (1.00 - 1.01, p=.185) | ||
| %PTH | 1.10 (1.04 - 1.15, p<.001) | 1.03 (0.97 - 1.09, p=.357) | |
| Scr(µmol/L) | 1.00 (1.00 - 1.00, p=.935) | ||
| Bun(mmol/L) | 1.04 (0.99 - 1.10, p=.143) | ||
| CYSC(mg/L) | 1.09 (0.89 - 1.34, p=.419) | ||
| UA(µmol/L) | 1.00 (1.00 - 1.00, p=.844) | ||
| ALP(U/L) | 1.01 (1.00 - 1.01, p<.001) | 1.00 (1.00 - 1.01, p=.151) | |
| ALB(g/L) | 0.96 (0.89 - 1.04, p=.287) | ||
| TG(mmol/L) | 0.80 (0.53 - 1.21, p=.290) | ||
| TC(mmol/L) | 1.36 (0.98 - 1.88, p=.067) | ||
| HDL(mmol/L) | 2.11 (0.77 - 5.73, p=.144) | ||
| LDL(mmol/L) | 1.59 (0.93 - 2.70, p=.088) |